DRTS Stock Analysis: Buy, Sell, or Hold?
DRTS - Alpha Tau Medical Ltd. Ordinary Shares
$14.43
-0.01 (-0.07%)
âŧ
5d:
-1.3%
30d:
+4.04%
90d:
+49.07%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 28, 2026 at $14.53 · last confirmed Sep 9, 2026
Strength: 8.0/10
Get Alerted When DRTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: DRTS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: DRTS is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: DRTS is currently trading at $14.43, which is considered fair relative to its 30-day fair value range of $13.47 to $14.87.
Technical Outlook: Technically, DRTS is in a strong uptrend. Immediate support is located at $13.65, while resistance sits at $15.17.
Market Sentiment: DRTS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.80 (+23.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, DRTS is in a strong uptrend. Immediate support is located at $13.65, while resistance sits at $15.17.
Market Sentiment: DRTS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $17.80 (+23.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$13.47 -
$14.87
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
50.0%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.4% below Wall St target ($17.80)
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$13.47 -
$14.87
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$13.65
Resistance Level
$15.17
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-26.99
Wall Street Target
$17.80
(+23.4%)
Share & Embed Analysis
Last updated: September 12, 2026 11:07 PM ET
Data refreshes hourly during market hours. Next update: 12:07 AM
Data refreshes hourly during market hours. Next update: 12:07 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$88 | 50 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 49 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
RCKT
Rocket Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$9 | 41 HOLD |
|
LRMR
Larimar Therapeutics Inc |
STRONG BUY
11 analysts |
$14 | 58 HOLD |
